FORM 6

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a - 16 or 15d - 16 of

the Securities Exchange Act of 1934

 

For the month of May, 2003

Commission File Number: 1-10817

 

CELLTECH GROUP PLC

(Translation of registrant's name into English)

 

208 Bath Road, Slough, Berkshire SL1 3WE ENGLAND

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F X      Form 40-F

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes          No X

 

(If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________).

 

 

Enclosure: Holding(s) in Company released 01 May, 2003

 

SCHEDULE 10

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Name of company
 

Celltech Group plc

2. Name of shareholder having a major interest
 

The Capital Group Companies, Inc. on behalf of its affiliates, including Capital International S.A., Capital International, Inc., Capital Guardian Trust Company and Capital International Limited

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18
 

As in 2 above

4. Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them
 

State Street Nominees Limited

1,700

Bank of New York Nominees

29,700

Chase Nominees Limited

1,318,700

Citibank London

106,100

Nortrust Nominees

848,300

Mellon Nominees (UK) Limited

44,600

State Street Nominees Limited

298,200

Bank of New York Nominees

5,230,799

Northern Trust

1,401,602

Chase Nominees Limited

3,460,263

Midland Bank plc

157,100

Bankers Trust

2,310,800

Barclays Bank

60,000

Citibank London

53,000

Morgan Guaranty

315,500

Nortrust Nominees

2,579,906

State Street Bank & Trust Co.

179,600

Deutsche Bank AG

886,000

HSBC Bank plc

1,073,300

Mellon Bank N.A.

230,300

Northern Trust AVFC

196,436

KAS UK

57,210

Mellon Nominees (UK) Limited

63,500

Bank One London

103,200

State Street Nominees Limited

35,593

Chase Nominees Limited

862,800

Midland Bank plc

15,700

Barclays Bank

56,800

Royal Bank of Scotland

855,000

State Street Bank & Trust Co.

70,800

Lloyds Bank

68,700

RBSTB Nominees Ltd

81,000

Citibank NA

17,600

HSBC Bank plc

200,200

State Street Nominees Limited

579,959

Bank of New York Nominees

138,400

Chase Nominees Limited

759,000

Citibank London

10,000

Nortrust Nominees

233,700

State Street Bank & Trust Co.

14,999

Citibank NA

98,400

Chase Manhattan Nominee Ltd

5,300

HSBC Bank plc

47,400

5. Number of shares / amount of stock acquired
 

2,824,766 (since last notification)

6. Percentage of issued class
 

1.01%

7. Number of shares / amount of stock disposed
 

N/a

8. Percentage of issued class
 

N/a

9. Class of security
 

Ordinary 50p Shares

10. Date of transaction
 

29 April 2003

11. Date company informed
 

1 May 2003

12. Total holding following this notification
 

25,157,167

13. Total percentage holding of issued class following this notification
 

9.06%

14. Any additional information
 

 


 

15. Name of contact and telephone number for queries
 

Cheryl Cramer

Tel. 01753 447933

16. Name and signature of authorised company official responsible for making this notification
 

J A D Slater

Date of notification
 

1 May 2003

The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept any liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material contained in it, or from any action or decision taken as a result of using this document or any such material.

END

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

                                                                                                                                                           CELLTECH GROUP PLC
                                                                                                                                                           (Registrant)

 

 

                                                                                                                                                           By: /s/ PETER ALLEN       
                                                                                                                                                           Peter Allen
                                                                                                                                                           Chief Financial Officer

 

Dated: 01 May, 2003